资讯

MyChesCo on MSN3 小时
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast Cancer
Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...